Physician profile
Julia E Tzu
NPI 1558558031
$1,774.80
in general payments reported to CMS, 2019-2025
16 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $184 · 2021: $240 · 2022: $239 · 2023: $189 · 2024: $387 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $461.91 | 2020-2025 | Otezla |
| Pfizer INC. | $321.00 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $272.32 | 2021-2025 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $151.44 | 2019-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.12 | 2019-2021 | |
| Dermavant Sciences, INC. | $84.08 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $53.98 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $49.24 | 2020 | |
| Epi Health, LLC | $42.03 | 2022 | |
| Celgene Corporation | $42.00 | 2019 | |
| Incyte Corporation | $35.12 | 2021-2022 | |
| Galderma Laboratories, L.P. | $32.72 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.51 | 2024 | Sotyktu |
| Botanix Sb INC | $21.22 | 2025 | Sofdra |
| Almirall LLC | $18.33 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Tzu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.